Search for a trial

THE HYDRUS II TRIAL:
A PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE
SAFETY AND EFFECTIVENESS OF THE HYDRUS IMPLANT FOR LOWERING INTRAOCULAR PRESSURE IN GLAUCOMA PATIENTS UNDERGOING CATARACT SURGERY

The purpose of this study is to expand knowledge of the IVANTIS Hydrus Implant's ability to decrease intraocular pressure (the pressure in the eye).

Efficacy and Safety of Brinzolamide 10 mg/ml / Brimonidine 2 mg/ml Eye Drops, Suspension Compared to Brinzolamide 10 mg/ml Eye Drops, Suspension plus Brimonidine 2 mg/ml Eye Drops, Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension.

The purpose of this research study is to demonstrate that the fixed combination brinz/brim used twice daily has a similar effect (both in terms of reduction of the eye pressure and possible side effects) as brinzolamide and brimonidine used twice…

A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to those of tafluprost 0.0015% and timolol 0.5% eye drops given as individual monotherapies in patients with open angle glaucoma or ocular hypertension

The objective of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to those of tafluprost 0.0015% and timolol 0.5% eye drops given as individual…

An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using DuoTrav APS Eye Drops Solution Versus XALACOM® Eye Drops Solution.

A new formulation of DuoTrav® eye drops, called DuoTrav APS, in which, the preservative (BAC) has been replaced by a new preservative called POLYQUAD has been developed. POLYQUAD is expected to be better tolerated in the eye, especially for the…

A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost
Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric
Glaucoma Patients

The primary objective of this study is to demonstrate that the IOP-lowering efficacy of Travoprost Ophthalmic Solution, 0.004% (preserved with POLYQUAD) is noninferior to Timolol Ophthalmic Solution (0.5% or 0.25%) in pediatric glaucoma patients.

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 2 dose strengths of Bimatoprost SR in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) after initial and repeated administrations